Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)

NACompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

October 31, 2017

Study Completion Date

March 31, 2018

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
OTHER

275mg Oligo Fucoidan + 275mg HS Fucoxanthin

Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.

OTHER

placebo pills

taking placebo pills as if patients are under treatment.

Trial Locations (1)

116

WanFangH, Taipei

All Listed Sponsors
lead

Taipei Medical University WanFang Hospital

OTHER

NCT02875392 - Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD) | Biotech Hunter | Biotech Hunter